English
Regional settings| Spread | 1.40 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ SEK 5,000.00 Short position overnight fee ~ SEK 4,000.00 | -0.02194% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ SEK 5,000.00 Short position overnight fee ~ SEK 4,000.00 | -0.000282% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | SEK | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Sweden | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 191.9 |
| Open | 193 |
| 1-Year Change | -18.2% |
| Day's Range | 193 - 198.1 |
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
BRIEF: For the fiscal year ended 31 December 2021, BioArctic AB revenues decreased 63% to SEK23.1M. Net loss applicable to common stockholders increased 75% to SEK119.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Labor & Related Expenses in SGA increase of 15% to SEK72.5M (expense).
